The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers
Open accessAbstract
Human rhinovirus (HRV) infections are usually self-limited but may be associated with serious consequences, particularly in those with asthma and chronic respiratory disease. Effective antiviral agents are needed for preventing and treating HRV illnesses. Ruprintrivir (Agouron Pharmaceuticals, Inc., San Diego, Calif.) selectively inhibits HRV 3C protease and shows potent, broad-spectrum anti-HRV activity in vitro. We conducted three double-blind, placebo-controlled clinical trials in 202 healthy volunteers to assess the activity of ruprintrivir in experimental HRV infection. Subjects were randomized to receive intranasal ruprintrivir (8 mg) or placebo sprays as prophylaxis (two or five times daily [2×/day or 5×/day] for 5 days) starting 6 h before infection or as treatment (5×/day for 4 days) starting 24 h after infection. Ruprintrivir prophylaxis reduced the proportion of subjects with positive viral cultures (for 5×/day dosing groups, 44% for ruprintrivir treatment group versus 70% for placebo treatment group [P= 0.03]; for 2×/day dosing groups, 60% for ruprintrivir group versus 92% for placebo group [P= 0.004]) and viral titers but did not decrease the frequency of colds. Ruprintrivir treatment reduced the mean total daily symptom score (2.2 for ruprintrivir treatment group and 3.3 for the placebo treatment group [P= 0.014]) by 33%. Secondary endpoints, including viral titers, individual symptom scores, and nasal discharge weights, were also reduced by ruprintrivir treatment. Overall, ruprintrivir was well tolerated; blood-tinged mucus and nasal passage irritation were the most common adverse effects reported. Pharmacokinetic analysis of plasma and nasal ruprintrivir concentrations revealed intranasal drug residence with minimal systemic absorption. Results from these studies in experimental rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Community study of role of viral infections in exacerbations of asthma in 9–11 year old children
Johnston, S. L., Pattemore, P. K., Sanderson, G., Smith, S., Lampe, F., Josephs, L., Symington, P., Toole, S. O., Myint, S. H., Tyrrell, D. A. J., et al. (1995) · BMJ · doi:10.1136/bmj.310.6989.1225 · Cited by 1,991
Viruses and bacteria in the etiology of the common cold
Mäkelä, M. J., Puhakka, T., Ruuskanen, O., Leinonen, M., Saikku, P., Kimpimäki, M., Blomqvist, S., Hyypiä, T., & Arstila, P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.539-542.1998 · Cited by 768
Frequency and natural history of rhinovirus infections in adults during autumn
Arruda, E., Pitkäranta, A., Witek, T. J., Doyle, C. A., & Hayden, F. G. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.11.2864-2868.1997 · Cited by 346
Self-citationIntranasal Interferon- 2, Treatment of Experimental Rhinoviral Colds
Hayden, F. G., & Gwaltney, J. M. (1984) · Journal of Infectious Diseases · doi:10.1093/infdis/150.2.174 · Cited by 109
Self-citationHayden, F. G., Coats, T., Kim, K., Hassman, H. A., Blatter, M. M., Zhang, B., & Liu, S. (2002) · Antiviral Therapy · doi:10.1177/135965350200700107 · Cited by 72
Self-citationIntranasal recombinant alfa-2b interferon treatment of naturally occurring common colds
Hayden, F. G., Kaiser, D. L., & Albrecht, J. K. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.2.224 · Cited by 70
Self-citationCombined antiviral-antimediator treatment for the common cold
Gwaltney, J. M., Winther, B., Patrie, J. T., & Hendley, J. O. (2002) · The Journal of Infectious Diseases · doi:10.1086/341455 · Cited by 69
Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers
Hsyu, P.-H., Pithavala, Y. K., Gersten, M., Penning, C. A., & Kerr, B. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.392-397.2002 · Cited by 49
Self-citation
Cited by
Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 727
Jacobs, S. E., Lamson, D. M., St. George, K., & Walsh, T. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-12 · Cited by 704
Role of viral infections in the development and exacerbation of asthma in children
Jartti, T., & Gern, J. E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.003 · Cited by 474
New treatment regimes for virus-induced exacerbations of asthma
Edwards, M. R., Kebadze, T., Johnson, M. W., & Johnston, S. L. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.09.005 · Cited by 30
Metadata
- Authors
- Hayden, F. G., Turner, R. B., Gwaltney, J. M., Chi-Burris, K., Gersten, M., Hsyu, P., Patick, A. K., Smith, G. J., & Zalman, L. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-12
- Volume
- 47
- Issue
- 12
- Pages
- 3907-3916
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2114626540
- Cited by
- 231
- References
- 8
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. https://app.cochat.ai/papers/10.1128/aac.47.12.3907-3916.2003
- The paper
- Hayden, F. G., Turner, R. B., Gwaltney, J. M., Chi-Burris, K., Gersten, M., Hsyu, P., Patick, A. K., Smith, G. J., & Zalman, L. S. (2003). Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.12.3907-3916.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.